(Q30383012)

English

Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. (English)

1 reference

Europe PubMed Central

19 September 2017

0 references

pulmonary tuberculosis

1 reference

based on heuristic

inferred from title

object named as

Ronald G Hall

1

0 references

object named as

Tawanda Gumbo

3

0 references

author name string

Richard D Leff

2

1 reference

Europe PubMed Central

19 September 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

19 September 2017

Pharmacotherapy

1 reference

Europe PubMed Central

19 September 2017

29

1 reference

Europe PubMed Central

19 September 2017

1468-1481

1 reference

Europe PubMed Central

19 September 2017

12

1 reference

Europe PubMed Central

19 September 2017

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

STREPTOMYCIN treatment of pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Mycobacterial efflux pumps and chemotherapeutic implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Treatment of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Isoniazid drug and food interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Using therapeutic drug monitoring to dose the antimycobacterial drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Liver injury during antituberculosis treatment: an 11-year study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Frequency and type of reactions to antituberculosis drugs: observations in routine treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Pyridoxine supplementation during isoniazid therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Reversible pellagra-like encephalopathy with ethionamide and cycloserine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Treatment of isoniazid-resistant pulmonary tuberculosis with ethambutol, rifampicin and capreomycin: a co-operative study in England and Wales.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The role of pyrazinamide in tuberculosis chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Isoniazid induction of antinuclear antibodies. A prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The nephrotoxicity of antimicrobial agents (second of three parts).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Basic Mechanisms of Chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Extensively drug-resistant tuberculosis in the United States, 1993-2007.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Toxic effect of streptomycin upon balance and hearing.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Pulmonary tuberculosis in patient on intermittent haemodialysis.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion ofMycobacterium tuberculosisin the Log Phase of Growth

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

THE EMERGENCE OF ISONIAZID-RESISTANT CULTURES IN PATIENTS WITH PULMONARY TUBERCULOSIS DURING TREATMENT WITH ISONIAZID ALONE OR ISONIAZID PLUS PAS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

A comparison of isoniazid-cycloserine with isoniazid-PAS in the therapy of cavitary pulmonary tuberculosis. X. A report of the Veterans Administration-Armed Forces cooperative study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

Evidence of genetic transmission in African iron overload.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

Results of a surveillance system for adverse effects in leprosy's WHO/MDT

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elimination of para-aminosalicylic acid in patients with liver disease and renal insufficiency

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifampicin, ethambutol and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EFFECTS of streptomycin on tuberculosis in man; preliminary statement

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pyrazinamide-isoniazid in tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A PILOT study of cycloserine toxicity; a United States Public Health Service Cooperative Clinical Investigation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The occurrence of hyperuricemia during pyrazinamide-isoniazid therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TREATMENT of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PREVENTION of streptomycin resistance by combined chemotherapy; a Medical Research Council investigation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ISONIAZID in combination with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; fifth report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amikacin in the treatment of pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ocular toxicity of ethambutol and its relation to dose

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amikacin-induced nephropathy: is there any protective way?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of pulmonary tuberculosis with increased dietary iron

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Global epidemiology of tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1592/PHCO.29.12.1468

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30383012&oldid=1628718284"